Cancer Research Annual Meeting 2010 Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujii, H.
Right arrow Articles by Shirai, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujii, H.
Right arrow Articles by Shirai, T.
[Cancer Research 60, 114-120, January 1, 2000]
© 2000 American Association for Cancer Research

Molecular Biology and Genetics

Frequent Genetic Heterogeneity in the Clonal Evolution of Gynecological Carcinosarcoma and Its Influence on Phenotypic Diversity1

Hiroaki Fujii2, Manabu Yoshida, Zhu Xue Gong, Toshiharu Matsumoto, Yoshitomo Hamano, Masaharu Fukunaga, Ralph H. Hruban, Edward Gabrielson and Toshikazu Shirai

Departments of Pathology II [H. F., Z. X. G., Y. H., T. S.], Pathology I [T. M.], and Obstetrics/Gynecology [M. Y.], Juntendo University School of Medicine, Tokyo 113-8421, Japan; Department of Pathology I, Jikei University School of Medicine, Tokyo, Japan [M. F.]; and Departments of Pathology [E. G., R. H. H.] and Oncology Center [E. G.], Johns Hopkins University School of Medicine, Baltimore, Maryland 21287


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Carcinosarcomas of the uterus, ovaries, and fallopian tubes are highly aggressive neoplasms with incompletely understood histogenesis. Although recent immunohistochemical, cell culture, and molecular genetic studies all favor these cancers to be monoclonal in origin, the extent of intratumoral genetic heterogeneity in these tumors with divergent histology has not been reported previously. For this study, we microdissected a total of 172 carcinomatous or sarcomatous foci from 17 gynecological carcinosarcomas and analyzed allelic status with 41 microsatellite markers on chromosomal arms 1p, 1q, 3p, 4q, 5q, 6q, 8p, 9p, 10q, 11p, 11q, 13q, 16q, 17p, 17q, 18q, and 22q. With the exception of a single case with microsatellite instability, we found shared allelic losses and retentions among multiple individually dissected foci of each case, strongly supportive of the concept of a monoclonal origin for these neoplasms. In eight of these cases, we also found heterogeneous patterns of allelic loss at limited numbers of chromosomal loci in either the carcinomatous or sarcomatous components of the neoplasms. These heterogeneous patterns of allelic losses were consistent with either genetic progression or genetic diversion occurring during the clonal evolution of these neoplasms. In two cases, we found the specific patterns of genetic progression to be consistent with sarcomatous components of the neoplasms arising from carcinomatous components. We conclude that most of the gynecological carcinosarcomas have a monoclonal origin, and that genetic progression and diversion parallel the development of divergent phenotypes in these tumors. Because phenotypically divergent areas of the tumors share numerous genetic alterations, this divergence most likely occurs relatively late in the evolution of these tumors.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
CSs3 of the female genital tract are uncommon but clinically highly aggressive neoplasms with biphasic histology of carcinomatous and sarcomatous elements (1, 2, 3) . These neoplasms are usually large and bulky tumors and have often spread beyond the primary organ at the time of initial surgery (3, 4, 5) . Histologically, the carcinomatous components can include endometrioid, clear cell, serous, squamous, or mucinous differentiation, or they may be undifferentiated. Sarcomatous components include homologous (endometrial stromal sarcoma, fibrosarcoma, and leiomyosarcoma) elements and, in up to 50% of cases, heterologous (chondrosarcoma, osteosarcoma, rhabdomyosarcoma, and liposarcoma) elements.

Because these tumors have an intimate admixture of histologically diverse malignant cells, the histogenesis of CSs has long been a matter of speculation and dispute (2 , 3 , 6 , 7) . Three main hypotheses exist to explain these diverse histological elements. In the "collision tumor theory," synchronous biclonal tumors are thought to blend together to form CS histology. In the "composition theory," the stromal element is thought to be reactive and not neoplastic. This second theory has largely been abandoned because metastatic foci also frequently contain malignant stromal elements as well as malignant epithelial elements. The third, and most favored theory, is the "combination tumor theory," which postulates that both elements originate from a single stem cell clone. According to this theory, the sarcomatous component arises in a carcinoma through evolution of subclones, and thus the carcinomatous component is the primary determinant of their behavior and prognosis (8 , 9) .

A number of recent cell culture, immunohistochemistry, and molecular genetic studies support the monoclonal nature of these neoplasms. For example, cell lines established from CSs have been shown to differentiate into epithelial, mesenchymal, or both components under various culture conditions (10, 11, 12, 13) . Furthermore, immunohistochemical studies have documented the expression of epithelial markers in the sarcomatous components of a large proportion of cases (13, 14, 15, 16, 17, 18, 19) . More recently, X-chromosomal inactivation assays, p53 mutational analyses, and LOH studies have all shown the carcinomatous and sarcomatous elements to share common genetic alterations (20, 21, 22, 23, 24) .

Although these recent studies provide convincing evidence to support the monoclonal origin of these cancers, genetic diversity corresponding to phenotypic diversity has not been reported previously. It is possible to follow the clonal evolution of cancers with markers to identify LOH. In our previous studies of breast cancer progression, we evaluated LOH on multiple chromosomal regions in multiple individually microdissected foci of ductal carcinoma in situ and found patterns of LOH consistent with genetic progression and heterogeneity superimposed on homogeneous genetic changes (25, 26) . For this study, we have used a similar approach to evaluate the genetic evolution of gynecological CSs. Loss of specific alleles at 17 chromosomal loci suspected to harbor tumor suppressor genes was characterized using microsatellite markers in multiple individually microdissected foci of these cancers, and by comparing LOH patterns, we deduced the likely order of genetic changes in the evolution of individual tumors.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Tissues.
Cases of gynecological CS were identified in the archival pathology files of Juntendo University and Jikei University, confirmed by review of histopathology and tested for the quality of DNA preservation. Of the 17 cases identified, 12 cases originated in the uterus, 3 cases originated in the ovary, and 2 in the fallopian tube (summarized in Table 1Citation ). Heterologous elements were identified in 14 cases, and the remaining 3 cases contained only homologous elements. Coexsistence of other gynecological tumors was identified in case CS2 (CS in the uterus, endometrioid carcinoma in the bilateral ovaries), case CS9 (CS in the uterus and endometrioid carcinoma in the left ovary), and case CS21 (CS in the left fallopian tube and endometrioid carcinoma in the ovary and the uterus).


View this table:
[in this window]
[in a new window]

  		Table 1 Summary of carcinosarcoma cases and their genetic changes

For each case, location, histology (homologous or heterologous), number of tumor foci dissected, results for microsatellite analysis, and deduced genetic patterns are presented.

 
Microdissection and DNA Extraction.
Serial 8-µm sections were cut, deparaffinized, stained with H&E, visualized with an inverted microscope, and microdissected using a 26-gauge needle. Three to 34 carcinomatous and sarcomatous foci were individually microdissected from each neoplasm (Fig. 1)Citation . In case CS1 and case CS21, metastatic foci were also microdissected. A total of 172 foci were microdissected from the 17 cases. Normal control tissue was also dissected from the adjacent nonmalignant stroma, epithelium, or inflammatory infiltrates. Microdissected tissue was digested overnight at 50°C in buffer containing 0.5% NP40, 50 mM Tris-HCl (pH 8.0), 1 mM EDTA, and 200 µg/ml proteinase K. The lysate was heated at 95°C for 10 min and was stored at -20°C until used directly in PCR reaction.



View larger version (145K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Representative histology of CS case CS1 showing separately dissected carcinoma and sarcoma foci. T#, dissected foci serially numbered; T1, carcinoma component; T2 and T4, sarcoma component.

 
Detection of LOH.
PCR reactions contained 1 µl of DNA lysate, 0.4 µM[{gamma}-32p]ATP radiolabeled microsatellite primer, 0.2 mM deoxynucleotide triphosphate, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 50 mM KCl, and 0.4 unit of Taq polymerase in a total reaction volume of 10 µl Taq was added to reactions prewarmed to 94°C (hot start PCR), and samples were amplified with 35 cycles of PCR amplification. PCR products were separated on a 5% denaturing polyacrylamide-urea-formamide gel, and LOH was determined by more than a 75% reduction of the intensity in one of the two alleles as compared with those in normal control. When only a portion of the foci dissected from a single CS showed LOH, PCR reactions were repeated in duplicate to confirm the LOH and to exclude spurious PCR reactions. If necessary, microdissection was repeated.

All of the PCR primers for microsatellite markers were purchased from Research Genetics Co., Ltd. (Huntsville, AL). Microsatellite markers were selected to cover commonly deleted chromosomal regions in many of human tumors. The following primers were used: 1p and 1q (D1S500, D1S228, D1S158, and D1S318); 3p (D3S1286 and D3S1293); 4q (D4S424, D4S415, and D4S413); 5q (D5S2072, D5S421, and D5S1956); 6q (D6S264, D6S473, and D6S255); 8p (D8S255, D8S264, and D8S261); 9p (D9S1748 and D9S1749); 10q (D10S221, D10S219, and D10S574); 11p (D11S1324); 11q (D11S29 and Int2); 13q (D13S166 and D13S171); 16q (D16S265, D16S541, and D16S261); 17p (TP53, CHRNB1, and D17S786); 17q (D17S588 and D17S579); 18q (D18S46, D18S55, D18S474, and D18S487); and 22q (D22S270).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
One case, CS2, was exceptional in showing novel microsatellite alleles (microsatellite instability). All other tumors showed LOH homogeneously throughout the lesions at one to eight chromosomal loci (Table 1)Citation . The highest frequency of homogeneous LOH was seen on 17p (11 cases, 64.7%), followed by 9p (7 cases, 41.2%), 13q (6 cases, 35.3%), 4q (5 cases, 29.4%), 3p, 6q, 8p, and 18q (4 cases, 23.5%), 11q, 16q, 17q, and 22q (3 cases, 17.6%), chromosome 1 and 5q, (2 cases, 11.8%), 11p (1 case, 5.9%), and 10q (0 cases). On average, 3.65 chromosomal arms showed LOH.

In eight of these cases, all tumor foci examined showed identical patterns of loss or retention at all alleles tested. Although each of these tumors had a distinctive bidirectional phenotype, no genetic heterogeneity could be detected.

In contrast to these neoplasms with homogeneous LOH, heterogeneous patterns of LOH were noted among individually microdissected foci in eight cases (cases CS1, CS3, CS4, CS5, CS6, CS18, CS19, and CS21). Heterogeneous LOH occurred with one of the following patterns: (a) identical LOH at some loci (consistent with monoclonal origin) and identical additional alleles lost in both carcinoma foci and sarcoma foci of metastatic tumor (one case, CS1; Fig. 2Citation ); (b) additional LOH consistent with genetic progression in some of the sarcoma foci (one case, CS19; Fig. 3Citation ); (c) additional LOH consistent with genetic progression in some of the carcinoma foci (two cases, CS6 and CS18); (d) differing LOH consistent with genetic diversion in some of the carcinoma and sarcoma foci (two cases, CS4 and CS5); (e) additional LOH consistent with genetic progression from original carcinoma to CS only in metastatic foci (one case, CS21; Fig. 4Citation ); and (f) additional LOH consistent with genetic progression and diversion from original carcinoma to carcinoma/sarcoma foci (one case, CS3; Fig. 5Citation ).



View larger version (37K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Representative microsatellite amplifications of CS1 and proposed sequence of genetic changes and their phenotypic relationship. N, normal control DNA; T, tumor foci dissected separately; C, carcinomatous foci; S, sarcomatous foci; OV, ovary; LM, lung metastasis; Met, metastasis; dot, normal alleles; arrowheads, uniform allelic losses throughout the dissected foci; arrows, heterogeneous allelic losses observed only in some of the dissected metastatic CS foci. and : both carcinoma ( and ) and sarcoma ( and ) showing exactly the same genetic alteration. Increasing intensity demonstrate advanced but shared genetic changes in both carcinoma and sarcoma components.

 


View larger version (45K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Representative microsatellite amplifications of CS19 and proposed sequence of genetic and phenotypic evolution. N, normal control DNA; T, tumor foci dissected separately; C, carcinomatous foci; S, sarcomatous foci; dot, normal alleles; arrowheads, uniform allelic losses throughout the dissected foci; arrows, heterogeneous allelic losses observed only in some of the dissected sarcoma foci. : both carcinoma ( ) and sarcoma ( ) showing exactly the same genetic alteration; , sarcomatous foci with more advanced genetic changes.

 


View larger version (40K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Representative microsatellite amplifications of CS21 and proposed sequence of genetic and phenotypic evolution. N, normal control DNA; T, tumor foci dissected separately; C, carcinomatous foci; S, sarcomatous foci; dot, normal alleles; arrowheads, uniform allelic losses throughout the dissected foci; arrows, heterogeneous allelic losses observed only in dissected carcinoma/sarcoma foci in the fallopian tube; Ov, ovary; FT, fallopian tube; Ut, uterus. and , carcinomatous foci or subclones with increasing intensity representing accumulation of successive genetic changes; : both carcinoma ( ) and sarcoma ( ) showing exactly the same genetic alteration.

 


View larger version (51K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Representative microsatellite amplifications of CS3 and proposed sequence of its genetic and phenotypic evolution. N, normal control DNA; T, tumor foci dissected separately; C, carcinomatous foci; S, sarcomatous foci; dot, normal alleles; arrowheads, uniform allelic losses throughout the dissected foci; arrows, heterogeneous allelic losses observed only parts of the dissected carcinoma or sarcoma foci; and , carcinomatous foci or subclones with increasing intensity representing accumulation of successive genetic changes; , , , and , sarcomatous foci with increasing intensity representing accumulation of advanced genetic changes.

 
In addition to these complex patterns of genetic progression and diversion, one case (CS2) was exceptional in that extensive microsatellite instability of most of the microsatellite markers was noted in both carcinomatous and sarcomatous foci. Although many similar new alleles were identified within carcinoma foci or sarcoma foci independently, only a few of the new alleles were shared between carcinoma and sarcoma foci. This strongly suggested the biclonal nature of the uterine CS lesion in this case. An ovarian endometrioid carcinoma occurring in the same individual did not show any of these allelic changes and thus most likely represents a third primary tumor.

Patterns of chromosomal loss (i.e., homogeneous or heterogeneous) in the different neoplastic components of the CSs are summarized in Fig. 6Citation . Loss of several chromosomal arms (17p, 3p, 4q, 6q, 9p, 13q, and 22q) is relatively homogeneous throughout different regions of the tumors. These homogeneous patterns of LOH suggest that these genetic changes occurred relatively early in the clonal evolution of these neoplasms. Conversely, other chromosomal losses (10q, 11p, 11q, 1p, and 1q) were commonly seen in some but not all areas of the neoplasms. These heterogeneous patterns of LOH suggest that these genetic alterations occurred relatively late in the development of the neoplasms. Notably, LOH of 10q was found in only metastases of two cases. The possibility that inactivation of PTEN or another gene on 10q contributes to metastases of these cancers warrants further investigation.



View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Cumulated frequency of particular chromosomal loss according to carcinomatous and sarcomatous foci. {square}, number of cases with homogenous LOH; , number of cases with heterogeneous LOH in which only part of carcinomatous foci showed LOH; , number of cases with heterogeneous LOH in which only part of sarcomatous foci showed LOH; , number of cases with heterogeneous LOH in which part of both carcinomatous and sarcomatous foci showed LOH; , number of cases with heterogeneous LOH in which only metastatic carcinomatous and sarcomatous foci showed LOH.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Although cancers have long been recognized to consist of clonal populations of cells, only recently have some neoplastic lesions have been shown to have genetically heterogeneous elements (25, 26, 27, 28, 29, 30, 31, 32) . In many situations, genetic heterogeneity occurs in tumors that have a relatively homogeneous histological appearance. For example, we recently described substantial genetic heterogeneity in early in situ carcinoma of the breast.

It is reasonable to question whether genetic heterogeneity can account for the phenotypic divergence of CSs, which have been shown previously to originate from a single clone. Since the first description by Virchow (8 , 44) , CSs have been reported in ever-increasing number of locations in the human body, such as gastrointestinal tract, upper aerodigestive tact, lung, breast, and genitourinary tract (8 , 33, 34, 35, 36, 37) . To undertake our study of gynecological CSs, we examined numerous individually microdissected foci of both carcinomatous and sarcomatous cells for LOH using microsatellite markers. Sixteen of the 17 cases we studied showed allelic losses shared by all tumor foci, consistent with a monoclonal origin for these tumors. In eight of the cases, all of the dissected foci shared homogeneous genetic changes in both carcinomatous and sarcomatous areas, and no discordant losses were identified. These findings strongly indicate the totipotential nature of the single tumor clone and hence support the combination theory of CS histogenesis.

In addition to this extensive sharing of chromosomal changes, we also noted evidence for genetic progression or genetic diversion within eight of the tumors. In these tumors, we found LOH of additional chromosomal arms in some of the dissected foci (progression) or differing patterns of LOH of one or more chromosomal arms (diversion). Summarizing the pattern of genetic changes observed in our cases, we hypothesize several possible genetic and phenotypic relationships in the clonal evolution of gynecological CSs as shown in Fig. 7Citation . For each tumor, there appears to be a totipotential clone from which all other portions of the tumor evolve. An original clone of a pure carcinoma can then apparently acquire carcinosarcomatous or sarcomatous phenotype by successive genetic changes (CS3 and CS21). On the other hand, we saw no evidence for tumors in which a sarcoma appeared to give rise to carcinosarcomatous or carcinomatous subclones.



View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 7. Genetic evolution of CS. Accumulation and diversion of genetic changes in the clonal evolution of gynecological CSs and their relationship with histological/phenotypic diversity is summarized. , and , carcinomatous foci or subclones. Increasing intensity represents accumulation of successive genetic changes; , and sarcomatous foci with increasing intensity representing accumulation of advanced or diverged genetic changes; X, no pathway has been demonstrated. Thus, a sarcoma clone giving rise to carcinoma or CS does not exist. Tumor extension and metastasis are also closely related to genetic progression and diversion.

 
The prognosis of CSs has been proposed to be related to characteristics of specific histological elements, but there is no agreement concerning which histological elements determine the prognosis of these tumors. Sarcomatous components, and especially the presence of rhabdomyosarcomatous components, have been associated with poor outcome, but a number of studies have also emphasized the carcinomatous component as the primary determinant of prognosis (2 , 4 , 9 , 17 , 38 , 39) . Our data demonstrate both carcinomatous and sarcomatous foci to independently have the ability to acquire advanced genetic changes during the evolution of the tumor. It appears reasonable, therefore, that both components of the tumor should be considered when attempting to assess the malignant potential of a particular tumor.

Overall, the high percentage of loci with LOH in these tumors and the high frequency of genetic heterogeneity among different portions of tumors may be related to the relatively aggressive behavior of these cancers. We found the highest frequency of LOH on 17p, a chromosomal arm that includes the p53 locus, and frequent p53 mutations and overexpression have been reported previously in these neoplasms (19 , 20 , 22, 23, 24 , 40) . Because p53 overexpression and 17p LOH both occur concordantly in sarcomatous and carcinomatous components, we suspect that p53 is affected very early in the development of the majority of these tumors. Somewhat surprisingly, LOH of 10q was only infrequently noted in CSs. This chromosomal arm harbors the recently identified tumor suppressor PTEN, which is frequently mutated in endometrioid carcinoma (41, 42, 43) .

The results of our study raise the possibility that inactivation of PTEN, commonly seen in usual endometrial carcinoma, is a relatively uncommon event in the highly malignant CSs. LOH at the PTEN locus on 10q, when it does occur in CSs, may occur late in the progression of these neoplasms. In contrast, inactivation of p53 (and LOH of 17p) appear to be frequent in the pathogenesis of CSs, similar to what is seen in aggressive serous variants of endometrial adenocarcinoma. The possibility that PTEN and p53 alterations have significantly different prognostic implications in developing gynecological neoplasms warrants further investigation in larger samples of these cancers. Together, these findings suggest that CSs are genetically distinct from the majority of endometrial cancers.

In conclusion, our data support the concept that gynecological CSs are in most cases derived from a single clone. The extensive sharing of many genetic alterations by phenotypically diverse areas of tumors suggests that the phenotypic divergence occurs relatively late in the evolution of the cancers. Furthermore, we have demonstrated genetic heterogeneity to accompany the phenotypic divergence, with patterns of genetic alterations that are consistent with both progression and divergence within individual tumors.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by a research grant from the Ministry of Education, Science, Sports and Culture of Japan. Back

2 To whom requests for reprints should be addressed, at Department of Pathology II, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Phone: 03-5802-1039; Fax: 03-3813-3164; E-mail: hfujii{at}med.juntendo.ac.jp Back

3 The abbreviations used are: CS, carcinosarcoma; LOH, loss of heterozygosity. Back

Received 5/21/99. Accepted 10/28/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Gompel S., Silverberg S. G. Pathology in gynecology and obstetricsEd J. B. Lippincott 3, pp. 249–260. Philadelphia 1985.
  2. Silverberg S. G., Major F. J., Blessing J. A., Fetter B., Askin F. B., Liao S-Y., Miller A. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: a Gynecologic Oncology Group pathologic study of 203 cases. Int. J. Gynecol. Pathol., 9: 1-19, 1990.[Medline]
  3. Silverberg S. G. Mixed Müllerian tumors. Curr. Top. Pathol., 85: 35-56, 1992.[Medline]
  4. Schweizer W., Demopoulos R., Beller U., Dubin N. Prognostic factors for malignant mixed Müllerian tumors of the uterus. Int. J. Gynecol. Pathol., 9: 129-136, 1990.[Medline]
  5. Sartori E., Bazzurini L., Gadducci A., Landoni F., Lissoni A., Maggino T., Zola P., La Face B. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol. Oncol., 67: 70-75, 1997.[Medline]
  6. Meyer R. Mischgeschwülste des Uterus die komplizieretern tumoren Henke F. Lubarsch O. eds. . Handbuch der Speziellen Pathologischen Anatomie und Histologie, : 412-415, Julius Springer Berlin 1930.
  7. Gorstein F., Anderson T. L. Malignant mixed mesodermal tumors: carcinoma, sarcoma or both?. Hum. Pathol., 22: 207-209, 1991.[Medline]
  8. Wick M. R., Swanson P. E. Carcinosarcomas. Current perspectives and historical review of nosological concepts. Semin. Diagn. Pathol., 10: 118-127, 1993.[Medline]
  9. Colombi R. P. Sarcomatoid carcinomas of the female genital tract (malignant mixed Müllerian tumors). Semin. Diagn. Pathol., 10: 169-175, 1993.[Medline]
  10. Masuda A., Takeda A., Fukami H., Yamada C., Matsuyama M. Characteristics of cell lines established from a mixed mesodermal tumor of the human ovary. Carcinomatous cells are changeable to sarcomatous cells. Cancer (Phila.), 60: 2696-2703, 1987.[Medline]
  11. Emoto M., Iwasaki H., Kikuchi M., Ishiguro M., Kubota T., Izumi H., Shirakawa K., Kaneko Y. Two cell lines established from mixed Müllerian tumors of the uterus. Morphologic, immunocytochemical, and cytogenetic analyses. Cancer (Phila.), 69: 1759-1768, 1992.[Medline]
  12. Emoto M., Iwasaki H., Kikuchi M., Shirakawa K. Characteristics of cloned cells of mixed Müllerian tumor of the human uterus. Cancer (Phila.), 71: 3065-3075, 1993.[Medline]
  13. Gorai I., Doi C., Minaguchi H. Establishment and characterization of carcinosarcoma cell line of the human uterus. Cancer (Phila.), 71: 775-786, 1993.[Medline]
  14. Bitterman P., Chun B., Kurman R. J. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus: a clinicopathologic and immunohistochemical study. Am. J. Surg. Pathol., 14: 317-328, 1990.[Medline]
  15. Meis J. M., Lawrence W. D. The immunohistochemical profile of malignant mixed Müllerian tumor. Overlap with endometrial adenocarcinoma. Am. J. Clin. Pathol., 94: 1-7, 1990.[Medline]
  16. Costa M. J., Khan R., Judd R. Carcinosarcoma (malignant mixed Müllerian [mesodermal] tumor) of the uterus and ovary. Arch. Pathol. Lab. Med., 115: 583-590, 1991.[Medline]
  17. George E., Manivel J. C., Dehner L. P., Wick M. R. Malignant mixed Müllerian tumors: an immunohistochemical study of 47 cases with histogenetic considerations and clinical correlation. Hum. Pathol., 22: 215-223, 1991.[Medline]
  18. De Brito P. A., Silverberg S. G., Orenstein J. M. Carcinosarcoma (malignant mixed Müllerian [mesodermal] tumor)of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum. Pathol., 24: 132-142, 1993.[Medline]
  19. Mayall F., Rutty K., Campbell F., Goddard H. p53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology, 24: 211-214, 1994.[Medline]
  20. Costa M. J., Vogelsang J., Young L. J. T. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed Müllerian tumors): a clinicopathologic study of 74 cases. Mod. Pathol., 7: 619-627, 1994.[Medline]
  21. Thompson L., Chang B., Barsky S. H. Monoclonal origins of malignant mixed tumors (carcinosarcomas): evidence for a divergent histogenesis. Am. J. Surg. Pathol., 20: 277-285, 1996.[Medline]
  22. Abeln E. C. A., Smit V. T. H. B. M., Wessels J. W., De Leeuw W. J. F., Cornelisse C. J., Fleuren G. J. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed Müllerian tumors. J. Pathol., 183: 424-431, 1997.[Medline]
  23. Wada H., Enomoto T., Fujita M., Yoshino K., Nakashima R., Kurachi H., Haba T., Wakasa K., Shroyer K. R., Tsujimoto M., Hongyo T., Nomura T., Murata Y. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res., 57: 5379-5385, 1997.[Abstract/Free Full Text]
  24. Knounelis S., Jones M. W., Papadaki H., Bakker A., Swalsky P., Finkelstein S. D. Carcinosarcomas (malignant mixed Mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum. Pathol., 29: 82-87, 1998.[Medline]
  25. Fujii H., Marsh C., Cairns P., Sidransky D., Gabrielson E. Genetic divergence in the clonal evolution of breast cancer. Cancer Res., 56: 1493-1497, 1996.[Abstract/Free Full Text]
  26. Fujii H., Szumel R., Marsh C., Zhou W., Gabrielson E. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res., 56: 5260-5265, 1996.[Abstract/Free Full Text]
  27. Boland, C. R., Sato, J., Appelman, H. D., Bresalier, R. S., and Feinberg, A. P. Microallelotyping defines the sequence and tempo of allelic losses at tumor suppressor gene loci during colorectal cancer progression. Nat. Med., 1: 902–909.
  28. Shibata D., Navidi W., Salovaara R., Li Z-H., Aaltonen L. A. Somatic microsatellite mutations as molecular tumor clocks. Nat. Med., 2: 676-681, 1996.[Medline]
  29. Fujii H., Inagaki M., Kasai S., Miyokawa N., Tokusashi Y., Gabrielson E., Hruban R. H. Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas. Am. J. Pathol., 151: 1447-1454, 1997.[Abstract]
  30. Macintosh C. A., Stower M., Reid N., Maitland N. J. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res., 58: 23-28, 1998.[Abstract/Free Full Text]
  31. Jovanovic A. S., Boynton K. A., Mutter G. L. Uteri of women with endometrial carcinoma contain a histopathological spectrum of monoclonal putative precancers, some with microsatellite instability. Cancer Res., 15: 1917-1921, 1996.
  32. Mutter G. L., Boynton K. A., Faquin W. C., Ruiz R. E., Jovanovic A. S. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Cancer Res., 56: 4483-4486, 1996.[Abstract/Free Full Text]
  33. Weidner N., Zekan P. Carcinosarcoma of the colon. Report of a unique case with light and immunohistochemical studies. Cancer (Phila.), 58: 1126-1130, 1986.[Medline]
  34. Santeusanio G., Pascal R. R., Bisceglia M., Costantino A. M., Bosman C. Metaplastic breast carcinoma with epithelial phenotype of pseudosarcomatous components. Arch. Pathol. Lab. Med., 112: 82-85, 1988.[Medline]
  35. Pitts W. C., Rojas V. A., Gaffey M. J., Rouse R. V., Esteban J., Frierson H. F., Kempson R. L., Weiss L. M. Carcinomas with metaplasia and sarcomas of the breast. Am. J. Clin. Pathol., 95: 623-632, 1991.[Medline]
  36. Ro J. Y., Ayala A. G., Sella A., Samuels M. L., Swanson D. A. Sarcomatoid renal cell carcinoma: clinicopathologic study of 42 cases. Cancer (Phila.), 59: 516-526, 1987.[Medline]
  37. Young R. H. Carcinosarcoma of the urinary bladder. Cancer (Phila.), 59: 1333-1339, 1987.[Medline]
  38. Sreenan J. J., Hart W. R. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am. J. Surg. Pathol., 19: 666-674, 1995.[Medline]
  39. Mascasaet M. A., Waxman M., Fruchter R. G., Boyce J., Hong P., Nicastri A. D., Remy J. C. Prognostic factors in malignant mesodermal (Müllerian) mixed tumors of the uterus. Gynecol. Oncol., 20: 32-42, 1985.[Medline]
  40. Liu F-S., Kohler M. F., Marks J. R., Bast R. C., Jr., Boyd J., Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet. Gynecol., 83: 118-124, 1994.[Medline]
  41. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S. H., Giovanella B. C., Ittmann M., Tycko B., Hibshoosh H., Wingler M. H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Washington DC), 275: 1943-1947, 1997.[Abstract/Free Full Text]
  42. Tashiro H., Blazes M. S., Wu R., Cho K. R., Bose S., Wang S. I., Li J., Parsons R., Ellenson L. H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res., 57: 3935-3940, 1997.[Abstract/Free Full Text]
  43. Risinger J. I., Hayes A. K., Berchuck A., Barrett J. C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res., 57: 4736-4738, 1997.[Abstract/Free Full Text]
  44. Virchow, R. Die Krankhaften gerschwuste, Vol. 2, pp. 181–182. Berlin, Germany: Hischward, 1869.



This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
M. Saegusa, M. Hashimura, T. Kuwata, and I. Okayasu
Requirement of the Akt/{beta}-Catenin Pathway for Uterine Carcinosarcoma Genesis, Modulating E-Cadherin Expression Through the Transactivation of Slug
Am. J. Pathol., June 1, 2009; 174(6): 2107 - 2115.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. W. Klymkowsky and P. Savagner
Epithelial-Mesenchymal Transition: A Cancer Researcher's Conceptual Friend and Foe
Am. J. Pathol., May 1, 2009; 174(5): 1588 - 1593.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. R. Stringer, J. S. Larson, J. M. Fischer, M. Medvedovic, M. N. Hersh, G. P. Boivin, and S. L. Stringer
Modeling variation in tumors in vivo
PNAS, February 15, 2005; 102(7): 2408 - 2413.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
H Fujii, K Ichikawa, T Takagaki, Y Nakanishi, M Ikegami, S Hirose, and T Shimoda
Genetic evolution of {alpha} fetoprotein producing gastric cancer
J. Clin. Pathol., December 1, 2003; 56(12): 942 - 949.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I. Gonzalez-Garcia, R. V. Sole, and J. Costa
Metapopulation dynamics and spatial heterogeneity in cancer
PNAS, October 1, 2002; 99(20): 13085 - 13089.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
W G McCluggage
Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?
J. Clin. Pathol., May 1, 2002; 55(5): 321 - 325.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujii, H.
Right arrow Articles by Shirai, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujii, H.
Right arrow Articles by Shirai, T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online